In Reply Pahwa and Hauser raise legitimate concerns based on my Editorial.1 In the EASE LID study, amantadine extended release was found to demonstrate efficacy in a randomized double-blind placebo-controlled design for treatment of levodopa-induced dyskinesias (LID) in Parkinson disease (PD).2 Pahwa and Hauser have expressed concerns over aspects of amantadine therapy that I discussed in the Editorial1 following the EASE LID study and I would like to address each of their comments.
Wagle Shukla A. ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply. JAMA Neurol. 2017;74(12):1508. doi:10.1001/jamaneurol.2017.3211
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: